skip to main content

LVAD GI Bleeding Mechanism — EECC MCQ

Instant feedback + full explanation. One question, done properly.

HardCardiac DevicesLVAD GI Bleeding MechanismEECC

A 65-year-old man with end-stage HFrEF on an LVAD (HeartMate 3) presents with intermittent dark stools. Endoscopy reveals arteriovenous malformations (AVMs) in the stomach and small bowel. What is the pathophysiology?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Continuous-flow LVADs reduce pulsatility, which degrades von Willebrand factor (vWF) multimers through excessive shear stress, causing acquired von Willebrand syndrome and predisposing to GI bleeding from AVMs

GI bleeding is the most common adverse event with continuous-flow LVADs (occurring in 15-30% of patients). The pathophysiology involves: (1) acquired von Willebrand syndrome — continuous-flow pumps create high shear stress that cleaves large vWF multimers (essential for platelet adhesion), causing a bleeding diathesis; (2) GI AVM formation — loss of arterial pulsatility triggers angiodysplasia formation through a mechanism involving reduced intestinal mucosal perfusion and HIF-1α/VEGF-mediated angiogenesis (analogous to Heyde syndrome in aortic stenosis). The HeartMate 3 (centrifugal flow with artificial pulse) was designed to reduce this, and the MOMENTUM 3 trial showed lower pump thrombosis but GI bleeding rates remain significant. Management includes reducing anticoagulation intensity, octreotide, and endoscopic treatment.

Reference: ESC (2023): HF Guidelines; MOMENTUM 3 Trial